Should I buy or sell Atea Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" AVIR shares. View AVIR analyst ratings or view top-rated stocks .

How have AVIR shares performed in 2024?

Atea Pharmaceuticals' stock was trading at $3.05 at the beginning of the year. Since then, AVIR shares have increased by 22.0% and is now trading at $3.72. View the best growth stocks for 2024 here .

When is Atea Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AVIR earnings forecast .

How were Atea Pharmaceuticals' earnings last quarter?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) issued its earnings results on Wednesday, February, 28th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.03.

What ETFs hold Atea Pharmaceuticals' stock?

ETFs with the largest weight of Atea Pharmaceuticals (NASDAQ:AVIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and Amplify Treatments, Testing and Advancements ETF (GERM) . iShares U.S. Pharmaceuticals ETF (IHE) .

When did Atea Pharmaceuticals IPO?

Atea Pharmaceuticals (AVIR) raised $253 million in an initial public offering on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO.

How do I buy shares of Atea Pharmaceuticals?

Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free AVIR Stock Alerts

$3.72

+0.02 (+0.54%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.67
▼
$3.77
50-Day Range: $3.70
▼
$4.56
52-Week Range: $2.77
▼
$5.19

Volume: 217,747 shs
Average Volume: 433,499 shs
Market Capitalization: $313.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Atea Pharmaceuticals alerts:

Atea Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$327,852 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.76) to ($2.92) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.50 out of 5 stars

Medical Sector

869th out of 911 stocks

Pharmaceutical Preparations Industry

391st out of 411 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Atea Pharmaceuticals.

4.0

Short Interest

Percentage of Shares Shorted
2.26% of the float of Atea Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Atea Pharmaceuticals has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Atea Pharmaceuticals has recently decreased by 1.76%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Atea Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Atea Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVIR.

0.0

News and Social Media Coverage

Search Interest
Only 1 people have searched for AVIR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atea Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $327,852.00 in company stock.
Percentage Held by Insiders
14.50% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Atea Pharmaceuticals are expected to decrease in the coming year, from ($2.76) to ($2.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atea Pharmaceuticals is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atea Pharmaceuticals is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atea Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Atea Pharmaceuticals Stock (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

AVIR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVIR Stock News Headlines

March 27, 2024 | globenewswire.com

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

March 21, 2024 | edition.cnn.com

Atea Pharmaceuticals, Inc.

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 16, 2024 | finance.yahoo.com

AVIR Apr 2024 2.500 call

March 3, 2024 | finance.yahoo.com

AVIR Mar 2024 7.500 call

March 1, 2024 | markets.businessinsider.com

Atea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory Risks

March 1, 2024 | finanznachrichten.de

Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 29, 2024 | finance.yahoo.com

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 28, 2024 | benzinga.com

Recap: Atea Pharmaceuticals Q4 Earnings

February 28, 2024 | finance.yahoo.com

Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results

February 28, 2024 | globenewswire.com

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 21, 2024 | finance.yahoo.com

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

February 21, 2024 | globenewswire.com

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

February 13, 2024 | stockhouse.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. (AVIR) and Encourages Investors to Contact the Firm

January 10, 2024 | finance.yahoo.com

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

January 9, 2024 | msn.com

Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy

January 9, 2024 | msn.com

Atea gains after mid-stage data for lead asset in Hepatitis C

January 8, 2024 | finance.yahoo.com

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

January 6, 2024 | morningstar.com

Atea Pharmaceuticals Inc Ordinary Shares

January 6, 2024 | morningstar.com

Atea Pharmaceuticals Inc Ordinary Shares

January 3, 2024 | finance.yahoo.com

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

November 13, 2023 | finance.yahoo.com

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

November 9, 2023 | finance.yahoo.com

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

Q3 2023 Atea Pharmaceuticals Inc Earnings Call

November 8, 2023 | msn.com

Atea Pharmaceuticals GAAP EPS of -$0.40

November 8, 2023 | finance.yahoo.com

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

See More Headlines

Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AVIR
CUSIP: N/A
CIK: 1593899
Web: www.ateapharma.com
Phone: 857-284-8891
Fax: N/A
Employees: 75
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-135,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -23.07%
Return on Assets: -22.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.24
Quick Ratio: 18.24

Sales & Book Value

Annual Sales: $351.37 million
Price / Sales: 0.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.65 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 84,170,000
Free Float: 71,961,000
Market Cap: $317.32 million
Optionable: Optionable
Beta: 0.16

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Jean-Pierre Sommadossi Ph.D. (Age 68)
Founder, Chairman, CEO & President
Comp: $1.1M
Ms. Andrea J. Corcoran J.D. (Age 62)
CFO, Executive VP of Legal & Secretary
Comp: $732.45k
Mr. John F. Vavricka (Age 60)
Chief Commercial Officer
Comp: $581.11k
Dr. Janet M. J. Hammond M.D. (Age 63)
Ph.D., Chief Development Officer
Comp: $817.16k
Dr. Maria Arantxa Horga M.D. (Age 55)
Chief Medical Officer
Comp: $695.85k
Mr. Wayne Foster CPA (Age 55)
Executive VP of Finance & Chief Accounting Officer
Ms. Jonae R. Barnes
Senior Vice President of Investor Relations & Corporate Communications
Mr. Ariyapadi N. Krishnaraj
Vice President of Marketing
Mr. Adel Moussa Ph.D.
Executive Vice President of Chemistry
Mr. Xiao-Jian Zhou Ph.D.
Executive Vice President of Early Stage Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVIR Stock Analysis - Frequently Asked Questions

Should I buy or sell Atea Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" AVIR shares.
View AVIR analyst ratings or view top-rated stocks.
How have AVIR shares performed in 2024?: Atea Pharmaceuticals' stock was trading at $3.05 at the beginning of the year. Since then, AVIR shares have increased by 22.0% and is now trading at $3.72.
View the best growth stocks for 2024 here.
When is Atea Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AVIR earnings forecast.
How were Atea Pharmaceuticals' earnings last quarter?: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) issued its earnings results on Wednesday, February, 28th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.03.

What ETFs hold Atea Pharmaceuticals' stock?: ETFs with the largest weight of Atea Pharmaceuticals (NASDAQ:AVIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and Amplify Treatments, Testing and Advancements ETF (GERM).iShares U.S. Pharmaceuticals ETF (IHE).
When did Atea Pharmaceuticals IPO?: Atea Pharmaceuticals (AVIR) raised $253 million in an initial public offering on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO.
How do I buy shares of Atea Pharmaceuticals?: Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVIR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Atea Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Atea Pharmaceuticals Stock (NASDAQ:AVIR)

AVIR Stock Price History

AVIR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AVIR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™